HCPCS code J9311: Rituximab-hyaluronidase, per 10 mg2026 Medicare rate & RVUs in Illinois
Reports subcutaneous rituximab combined with hyaluronidase for treatment of certain B-cell cancers, with each unit representing 10 mg of rituximab.
CMS doesn’t publish an office rate for J9311 in Illinois.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9311 covers
This code identifies the subcutaneous combination of rituximab and hyaluronidase used to treat certain B-cell cancers, including follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. Oncology practices typically administer it in a clinic or infusion center. Patients receive a full dose of rituximab by intravenous infusion before starting the subcutaneous formulation.
Each billing unit represents 10 mg of rituximab in the combination; report units based on the amount administered. CMS assigns physician fee schedule status E, excluding the code from the physician fee schedule. When Medicare covers the drug, it pays under another payment method; HCPCS classifies it as a Part B drug, generally priced from CMS quarterly Average Sales Price files. Special Medicare coverage instructions apply.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9311 pays more and less in Illinois
The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.
| Payment locality | Office | Facility |
|---|---|---|
| Chicago, IL | Unavailable | Unavailable |
| East St. Louis, IL | Unavailable | Unavailable |
| Rest of Illinois | Unavailable | Unavailable |
| Suburban Chicago, IL | Unavailable | Unavailable |
How the J9311 rate is calculated
Each of J9311’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9311
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9311
J9311 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9311
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9311 isn’t priced in this setting.
J9311 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9312Rituximab injectionPer 10 mg
- Choose J9311 for the subcutaneous rituximab-hyaluronidase combination. J9312 reports rituximab without hyaluronidase and is associated with intravenous administration.
- J9301ObinutuzumabPer 10 mg
- J9301 is obinutuzumab, a different anti-CD20 drug. It is not the subcutaneous rituximab-hyaluronidase product.
- J9302Ofatumumab injectionPer 10 mg
- J9302 is ofatumumab, not rituximab. Select the code for the drug actually administered.
J9311 billing questions
How does J9311 differ from J9312?
J9311 is the subcutaneous rituximab-hyaluronidase combination. J9312 represents rituximab without hyaluronidase, generally used for intravenous administration.
What does one unit represent?
One unit represents 10 mg of rituximab. Calculate units from the rituximab amount administered.
Which administration service is associated with J9311?
The subcutaneous antineoplastic administration code 96401 may be reported for the administration when its requirements are met. The drug code reports the medication, not the administration service.
Does physician fee schedule status E mean Medicare never pays for J9311?
No. Status E means CMS excludes the code from the physician fee schedule. When Medicare covers the drug, payment is under another method, generally using the Part B drug ASP pricing files.
What should the record support?
Document the drug administered, the amount of rituximab given, and the subcutaneous route. The reported units should match the administered rituximab dose in 10 mg increments.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9311 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist